Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial
William D. Tap, Zsuzsanna Papai, Brian A. Van Tine, Steven Attia, Kristen N. Ganjoo, Robin L. Jones, Scott Schuetze, Damon Reed, Sant P. Chawla, Richard F. Riedel, Anders Krarup-Hansen, Maud Toulmonde, Isabelle Ray-Coquard, Peter Hohenberger, Giovanni Grignani, Lee D. Cranmer, Scott Okuno, Mark Agulnik, William Read, Christopher W. RyanThierry Alcindor, Xavier F.Garcia del Muro, G. Thomas Budd, Hussein Tawbi, Tillman Pearce, Stew Kroll, Denise K. Reinke, Patrick Schöffski
Dive into the research topics of 'Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial'. Together they form a unique fingerprint.